Clovis Oncology (CLVS) Shares Sold by Macquarie Group Ltd.
Macquarie Group Ltd. cut its position in shares of Clovis Oncology (NASDAQ:CLVS) by 88.6% in the fourth quarter, HoldingsChannel reports. The firm owned 100,200 shares of the biopharmaceutical company’s stock after selling 778,330 shares during the period. Macquarie Group Ltd.’s holdings in Clovis Oncology were worth $1,800,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in CLVS. Samlyn Capital LLC purchased a new position in shares of Clovis Oncology in the 4th quarter valued at $18,054,000. Orbimed Advisors LLC increased its holdings in shares of Clovis Oncology by 23.2% in the 4th quarter. Orbimed Advisors LLC now owns 2,752,200 shares of the biopharmaceutical company’s stock valued at $49,430,000 after acquiring an additional 517,630 shares during the period. Elk Creek Partners LLC purchased a new position in shares of Clovis Oncology in the 4th quarter valued at $6,828,000. Dimensional Fund Advisors LP purchased a new position in shares of Clovis Oncology in the 4th quarter valued at $5,641,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Clovis Oncology in the 3rd quarter valued at $4,406,000.
Shares of CLVS stock opened at $24.34 on Wednesday. Clovis Oncology has a 1-year low of $11.50 and a 1-year high of $65.24. The company has a current ratio of 4.55, a quick ratio of 4.34 and a debt-to-equity ratio of 3.93. The firm has a market cap of $1.33 billion, a P/E ratio of -3.44 and a beta of 2.08.
Several brokerages recently weighed in on CLVS. Zacks Investment Research downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Monday. JPMorgan Chase & Co. restated a “hold” rating on shares of Clovis Oncology in a research note on Sunday. ValuEngine upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. BidaskClub downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, March 20th. Finally, SunTrust Banks boosted their target price on Clovis Oncology to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, February 27th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. Clovis Oncology presently has an average rating of “Hold” and a consensus price target of $44.78.
In other Clovis Oncology news, Director James C. Blair sold 17,056 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $27.79, for a total transaction of $473,986.24. Following the sale, the director now owns 13,439 shares in the company, valued at approximately $373,469.81. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Lindsey Rolfe sold 1,729 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $26.13, for a total value of $45,178.77. Following the sale, the insider now owns 20,953 shares in the company, valued at approximately $547,501.89. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,782 shares of company stock worth $576,755. 10.20% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Clovis Oncology (CLVS) Shares Sold by Macquarie Group Ltd.” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.watchlistnews.com/clovis-oncology-clvs-shares-sold-by-macquarie-group-ltd/2952537.html.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Recommended Story: Risk Tolerance
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.